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Background: Left ventricular hypertrophy has multiple aetiologies including diabetes and genetic factors. We
aimed to identify genetic variants predicting left ventricular hypertrophy in diabetic individuals.
Methods: Demographic, echocardiographic, prescribing, morbidity, mortality and genotyping databases connected
with the Genetics of Diabetes Audit and Research in Tayside, Scotland project were accurately linked using a
patient-specific identifier. Left ventricular hypertrophy cases were identified using echocardiographic data.
Genotyping data from 973 cases and 1443 non-left ventricular hypertrophy controls were analysed, investigating
whether single nucleotide polymorphisms associated with left ventricular hypertrophy in previous Genome Wide
Association Studies predicted left ventricular hypertrophy in our population of individuals with type 2 diabetes.
Meta-analysis assessed overall significance of these single nucleotide polymorphisms, which were also used to
create gene scores. Logistic regression assessed whether these scores predicted left ventricular hypertrophy.
Results: Two single nucleotide polymorphisms previously associated with left ventricular hypertrophy were
significant: rs17132261: OR 2.03, 95% CI 1.10-3.73, p-value 0.02 and rs2292462: OR 0.82, 95% CI 0.73-0.93 and p-value
2.26x10-3. Meta-analysis confirmed rs17132261 and rs2292462 were associated with left ventricular hypertrophy
(p=1.03x10-8 and p=5.86x10-10 respectively) and one single nucleotide polymorphisms in IGF1R (rs4966014) became
genome wide significant upon meta-analysis although was not significant in our study. Gene scoring based on
published single nucleotide polymorphisms also predicted left ventricular hypertrophy in our study.
Rs17132261, within SLC25A46, encodes a mitochondrial phosphate transporter, implying abnormal myocardial
energetics contribute to left ventricular hypertrophy development. Rs2292462 lies within the obesity-implicated
neuromedin B gene. Rs4966014 lies within the IGF1R1 gene. IGF1 signalling is an established factor in cardiac
hypertrophy.
Conclusions: We created a resource to study genetics of left ventricular hypertrophy in diabetes and validated our
left ventricular hypertrophy phenotype in replicating single nucleotide polymorphisms identified by previous
genome wide association studies investigating left ventricular hypertrophy.
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Cardiovascular complications are the most important
cause of mortality and morbidity in patients with type 2
diabetes mellitus (T2DM), accounting for around two
thirds of total mortality [1]. Increased cardiovascular risk
may be partly related to a direct adverse effect on the
heart in T2DM, independent of coronary artery disease
[2]. T2DM can directly affect the myocardium, promoting
left ventricular hypertrophy (LVH) [3].
LVH strongly predicts adverse cardiovascular sequelae
including overall cardiovascular mortality, myocardial
infarction, development of heart failure and cerebrovas-
cular events [4-7]. LVH is common in T2DM and
T2DM is an independent risk factor for LVH [8,9]. A
large proportion of patients with T2DM and no overt
cardiovascular disease have LVH [9]. Hypertension and
obesity often co-exist with T2DM, contributing to LVH
development. However, evidence shows LVH is inde-
pendently associated with T2DM when covariates such
as age, body mass index and hypertension are accounted
for [2,10,11]. Not all patients with T2DM develop LVH,
and those developing LVH do so to varying degrees [11].
This heterogeneity is likely to have a partial genetic basis.
Indeed, LV mass heritability in non-diabetic subjects has
been estimated through twin studies [12], studies in hyper-
tensive siblings [13] and through complex family studies
[14,15]. Maternally transmitted genetic susceptibility to
LVH in T2DM has also been reported [16].
These studies have prompted investigation of the gen-
etic basis of LVH through candidate gene studies and
genome wide association studies (GWAS). Early studies
seeking association between candidate genes and LVH
looked at exclusively hypertensive cohorts [17,18], whilst
other studies looked at candidate genes by comparing
monozygotic and dizygotic twins [19].
Two population-based GWAS have sought single nu-
cleotide polymorphisms (SNPs) associated with LVH in
the general population [20,21]. Vasan et al., using data
collected by the EchoGen consortium (n=12612), found
2 SNPs associated with increased LV mass and 3 SNPs
associated with increased LV wall thickness at genome
wide significance. These SNPs were not replicated in the
independent cohort [20]. Shah and colleagues looked at
3 population-based cohorts: The British Women's Heart
and Health Study (BWHHS, n=3443), the Genetic Regu-
lation of Arterial Pressure of Humans In the Community
(GRAPHIC) Study (n=2024) and the Whitehall II Study
(WHII) (n=5059). They found 4 SNPs associated with
LVH defined by ECG criteria with genome wide signifi-
cance and replicated in an independent cohort [21]. No
studies to date have identified genes predicting develop-
ment of LVH specifically in patients with T2DM.
Our LVH population is comprised of diabetic individuals
in Tayside participating in Go-DARTS, who underwentechocardiography for varying reasons. We aimed to iden-
tify individuals with echocardiographically defined LVH
and demonstrate its clinical impact. We sought to repli-
cate previous findings in non-diabetics in a large popula-
tion of patients with T2DM.
Methods
Go-DARTS population
The Diabetes Audit and Research Tayside, Scotland
(DARTS) project was based on linking clinical records by
a patient-specific identifier, the Community Health Index
(CHI) number, allowing the creation and maintenance of
sophisticated regional health informatics systems by the
Health Informatics Centre (HIC), University of Dundee.
The on-going DARTS project electronically followed all
living residents in Tayside, Scotland from 1 January 1996
(n=391 274 including 7 596 individuals with diabetes)
through linking the clinical datasets described below with
a high degree of reliability and accuracy. This approach
was well-validated in previous publications [22].
Data used for this comprehensive record linkage were
assimilated from multiple sources including the Com-
munity Health Index, containing demographic data,
the Scottish Morbidity Records providing International
Classification of Disease coding for hospital admissions
from 1980 until present, the General Registrars’ Office,
providing mortality data since 1998, the regional bio-
chemistry database, containing all biochemistry assays
performed from 1981 and data from all prescriptions
dispensed in Tayside since 1989 were also used.
These datasets were linked to genotyping data through
Go-DARTS, a genetic sub-study of DARTS comprised of
a cohort of Caucasian individuals with T2DM attending
diabetes clinics in Tayside [23]. Collection and analysis
of data in DARTS and Go-DARTS was approved by the
East of Scotland Research and Ethics Committee, in com-
pliance with the declaration of Helsinki. All participants
had given written consent for their data to be linked and
analysed for research purposes.
The Go-DARTS population has been extensively de-
scribed in previous studies [24,25]. Both the DARTS and
Go-DARTS studies received ethical approval from the local
boards. We studied 3641 individuals with T2DM recruited
to Go-DARTS between December 1998 and January 2008.
The Tayside echocardiography database
The Tayside echocardiography database, maintained by
the Department of Cardiology, contains data from
all clinically requested echocardiograms performed in
Ninewells Hospital, Dundee between 1994 and 2011.
Echocardiograms were reported by British Society of
Echocardiography (BSE) accredited echocardiographers.
This database was used to identify echocardiographically
defined cases of LVH and linked to the above datasets.
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the health informatics system at HIC to identify struc-
tural heart disease [26,27]. Written permission was
obtained from the echodatabase Caldicott guardian for
this data linkage.LVH phenotype definition
LV measurements were used to identify individuals with
LVH according to ASE criteria [28,29]. LV measurements
were used to calculate LV mass according to the formula:
LVmass ¼ 0:8 1:04 LVIDDþ LVPW þ IVSð Þˆ 3ð Þ‐ LVIDDð Þˆ 3ð Þ
  
þ 0:6
derived by Devereux et al. [29,30], where LVIDD repre-
sented left ventricular internal diameter in diastole, LVPW
referred to left ventricular posterior wall thickness and
IVS was septal thickness. LV mass was separately indexed
to height in metres to the power 2.7 and to body surface
area (BSA) using the formula [31]:
BSA ¼ weightð Þ0:425  heightð Þ0:725
 0:007184
Individuals were classed as having LVH if their LV
mass was outside the normal range when indexed to ei-
ther height or BSA using ASE cut-off values [28]. Partic-
ipants with LV wall thickness exceeding the normal
range according to direct 2D measures were also classed
as cases of LVH. Additionally, individuals were regarded
as having LVH if relative wall thickness (RWT) was in-
creased using the formula [32]:
RWT ¼ 2x LVPWð Þ=LVIDD
Hence, inclusion criteria for LVH cases were:
1) Diagnosis of type 2 diabetes mellitus
2) LVH on echocardiography according to any of the
above definitions using ASE cut-off values [28].
3) Absence of aortic stenosis greater than mild severity.
As aortic stenosis promotes LVH through increased
haemodynamic load on the left ventricle, these
patients were excluded from further analysis to
prevent confounding.
Genetic samples from individuals meeting all 3 inclu-
sion criteria were taken forward for further analysis.
Controls
Patients included in the analysis as control subjects met
with the following criteria:
1) Diagnosis of type 2 diabetes mellitus
2) No clinically requested echocardiogram
3) Never received a prescription for a loop diuretic.
Patients who had been prescribed a loop diuretic atany point were identified by extracting those with
prescriptions issued for BNF code 2.2.2.
Genetic samples from individuals meeting all 3 inclusion
criteria were taken forward for further analysis as non-LVH
controls, comparing them to LVH cases as defined above.
Glycaemic control
Mean glycosylated haemoglobin levels (HbA1C) were
calculated for cases and controls and compared.
Genotyping
Samples were genotyped at the Affymetrix service la-
boratory on the Genome-Wide Human SNP Array 6.0.
Genotype quality control was via the standard protocol
established for the Wellcome Trust Case Control Con-
sortium 2 Study.
Genotyping QC and sample QC
High density genotyping data were available for Go-
DARTS participants. Four thousand individuals with
T2DM typed on the Affymetrix 6.0 SNP genotyping array
and genotypes were imputed into this population from a
reference panel of HapMap2 individuals and a panel of
6000 British individuals typed on the Illumina dual using
IMPUTE2 [33,34].
Genotype data quality control of the discovery samples
was previously described [25,34,35].
Analysis and statistical approaches
Data were analysed using SAS 9.2 for Windows and the
R software [36]. Logistic regression analysis identified
covariates influencing case–control status using values
for clinical parameters (weight, height and blood pres-
sure) taken closest to the echocardiogram date in cases
of LVH and closest to the genotyping date in controls.
Covariates shown to be significant were accounted for
when genetic analysis was performed (see below). Sur-
vival analysis was used to show how LVH defined
according to the above phenotype influenced morbidity
and mortality to allow comparison with previous work.
Replication previously identified SNPs associated with LVH
Logistic and linear regression modelling were performed
assuming an additive genetic model using the PLINK
v1.07 software (http://pngu.mgh.harvard.edu/~purcell/
plink/ [37]) and imputed data were modelled using the
SCORE TEST in SNPTEST (https://mathgen.stats.ox.ac.
uk/genetics_software/snptest/snptest.html [38]) that took
genotype uncertainty into account. This allowed com-
parison of genetic variation at loci previously associated
with LVH between cases of LVH and controls. P values
less than 0.05 were taken as evidence of replication. Chi-
square tests of independence were used to test the
















Figure 1 Flow chart summarising inclusion and exclusion cases
and controls.
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analysis. Cases were then divided into those with in-
creased LV mass and those with concentric/eccentric re-
modelling and logistic regression modelling was repeated.
Survival analysis was performed to determine whether
variations in these replicated SNPs influenced the likeli-
hood of death and hospitalisation due to cardiovascular
illness.
Meta-analysis
Meta-analysis was performed to assess the likelihood the
above SNPs were associated with LVH when our data was
combined with published data. The odds ratios calculated
for the published SNPs were based on continuous data so
our binary case–control model was adjusted to allow com-
parison with published data. Continuous data for LV
thickness and LV mass were used as outcome measures.
Individual LV mass values were based on calculations
using the equation detailed above and values for LV thick-
ness were taken as the sum of the IVS and LVPW. A linear
regression model was used to determine whether pub-
lished SNPs associated with LV mass were associated with
continuous measures of LV mass in this study. Further
linear regression modelling was undertaken to assess
whether either of the published SNPs associated specific-
ally with LV thickness were associated with continuous
measures of LV thickness in this study. These results were
then meta-analysed using the weighted z values calculated
using the inverse variance-weighted z-score as described
by Bakker et al. [39] since the units used in the published
GWAS differed from our own.
Gene score calculation
SNPs discovered in GWAS meta-analyses [20,21] looking
at LVH were combined into a gene score by rating the
LVH raising allele by the meta-analysis effect using the
‘score’ option in PLINK [37].
SNPs discovered by Vasan et al. [20] were combined
to produce gene score 1, which included rs17568359,
rs7565161, rs7910620, rs2059238 and rs17132261. SNPs
discovered by Shah et al. [21] were combined to produce
gene score 2, including rs6797133, rs2292462, rs2290893
and rs4966014. All the above SNPs discovered by both
Vasan et al. and Shah et al. were combined to produce
gene score 3. Gene scores were then categorized by
quintiles and association with LVH was assessed by lo-
gistic regression analysis.
Results
Baseline characteristics LVH cases versus controls
The flow chart in Figure 1 summarises the selection of
cases of LVH and controls. As shown, 63% diabetic Go-
DARTS participants who had undergone echocardiog-
raphy had LVH.Mean baseline characteristics of cases of LVH and
controls are shown in Table 1. Logistic regression ana-
lysis indicated statistically significant differences between
cases of LVH and controls with all variables except gen-
der and systolic blood pressure. Differences in frequency
of comorbidities between cases of LVH and controls are
also shown in Table 1.
Survival analysis: outcomes in LVH cases versus controls
There were 356 (15%) deaths during the median follow
up period of 5.62 years (SD 2.64). Mortality in cases of
LVH exceeded that of controls as shown in Figure 2A.
There was a statistically significant difference in mortal-
ity comparing controls and cases (p<0.01, hazard ratio
2.44, 95% CI 1.93-3.09). There was also significantly in-
creased risk in LVH cases for composite outcome of
death or hospitalization due to cardiovascular disease
according to proportional hazard regression analysis
(p<0.01, hazard ratio 2.18, 95% CI 1.89-2.52) as shown
Figure 2B.
Logistic regression analysis and Co-variates
When testing the association with LVH, gender and sys-
tolic blood pressure were not statistically significant
while diastolic blood, height and age were significant.
These results are summarised in Table 1.
Previously characterised SNPs associated with LVH
Six out of nine SNPs previously associated with LVH
through GWAS had beta values showing the same
Table 1 Comparison of baseline characteristics in LVH cases versus non-LVH controls according to multiple logistic
regression analysis
Variable: mean (SD) Cases (n=973) Controls (n=1443) P value OR 95% CI
Male % 52.62 58.90 0.94 1.01 0.78-1.30
Age years 66.90 (9.83) 62.15 (11.10) <0.01 1.05 1.04-1.06
SBP mmHg 140.76 (23.07) 139.85 (17.47) 0.07 1.01 1.00-1.01
DBP mmHg 75.09 (13.48) 78.19 (9.97) <0.01 0.98 0.97-0.99
Height m 1.66 (0.09) 1.68 (0.10) <0.01 0.04 0.01-0.15
Weight kg 85.85 (18.76) 84.00 (17.10) <0.01 1.03 1.02-1.03
HbA1C % 7.70 (1.11) 7.63 (1.08) <0.01 1.2 1.11-1.31
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cant association with case–control status and had a minor
allele frequency (MAF) of 0.01 in our population. Our re-
sults showed every copy of the ‘T’ allele was associated
with increased risk of LVH (Table 2, p=0.02, beta 0.73, SE
0.31, OR 2.03, 95%CI 1.10-3.73). Rs2292462 showed a sig-
nificant association with LVH and had a MAF of 0.45 in
our population. Every copy of the ‘G’ allele was associ-
ated with decreased risk of LVH (Table 2, p=2.26 × 10-3,
beta −0.20, SE 0.06, OR 0.82, 95% CI 0.73-0.93).
Repeating the logistic regression analysis following div-
ision of cases into those with increased LV mass and
those with concentric/eccentric remodelling showed
rs17132261 remained significant (LV mass phenotype
p=0.01, increased wall thickness phenotype p=0.01) as
did rs2292462 (LV mass phenotype p<0.01, increased
wall thickness phenotype p<0.01).
Rs17132261 variation did not predict mortality and mor-
bidity, (Figure 3A, Table 2) but each copy of the ‘G’ allele
variant in rs2292462 showed a clear, dose-dependent rela-
tionship with cardiovascular hospitalization and mortality,
which was attenuated but remained significant when co-
variates were accounted for (Figure 3B, Table 2).Figure 2 Variation in survival time in cases of LVH versus non-LVH co
in LVH cases versus non-LVH controls. B - Kaplan-Meier plot illustrating diff
disease in LVH cases versus non-LVH controls.Meta-analysis results
Results from the meta-analyses are displayed in Table 2. A
total of 15 028 individuals were analysed for the SNPs pub-
lished by Vasan et al. [20] and 24 449 individuals were
analysed for the SNPs published by Shah et al. [21]. Investi-
gators within both of these studies sought to identify SNPs
associated with LVH, whilst Vasan and colleagues looked at
echocardiographically defined LVH, Shah and colleagues
looked at electrocardiographically defined LVH. Notably,
the combined p-values for rs7910620, rs17132261,
rs2292462 and rs4966014 exceeded the threshold for
genome wide significance (p<5.0 ×10 -8). Although not
significant in our study alone the significance for
rs4966014 had been previously published as 8x10-7 and
achieved genome wide significance (1.35x10-8) after the
addition of our data. This SNP lies within an intron of
the IGF1R gene.
Gene score calculation and association with LVH
Logistic regression analysis showed gene scoring based on
gene score 1 did not predict LVH. However, gene scores 2
and 3 were significant predictors of LVH, as summarised
in Table 3.ntrols. A – Kaplan-Meier plot illustrating difference in years to death
erence in years to death or hospitalization due to cardiovascular






















95% CIs for HR
rs17568359 Vasan et al. C 0.06 0.35 −4.78 8.53x10-8 −0.16 0.13 0.23 1.75x10-6 0.29 (0.10) 0.90 0.73-1.10
rs7565161 Vasan et al. A 0.44 0.75 −3.01 3.19x10-7 0.09 0.07 0.19 5.35x10-6 0.69 (0.06) 0.98 0.87-1.09
rs7910620 Vasan et al. G 0.01 1.00 0.17 5.62x10-9 −0.44 0.42 0.29 1.45x10-8 0.74 (0.58) 0.83 0.27-2.61
rs2059238 Vasan et al. A 0.23 0.31 −0.02 1.89x10-7 −0.06 0.07 0.45 5.07x10-7 0.56 (0.05) 1.03 0.93-1.15
rs17132261 Vasan et al. T 0.01 1.00 0.06 3.36x10-7 0.73 0.31 0.02 1.03x10-8 0.54 (0.20) 1.13 0.76-1.68
rs6797133 Shah et al. A 0.39 0.66 −3.7 1.2x10-7 3.73x10-3 0.06 0.95 2.42x10-7 0.74 (0.05) 1.02 0.92-1.12
rs2292462 Shah et al. G 0.45 0.06 −218.6 3.2x10-9 −0.20 0.06 2.26x10-3 5.86x10-10 <0.01 (0.05) 0.87 0.80-0.96
rs4966014 Shah et al. C 0.31 0.33 −181.8 1.3x10-7 −0.02 0.07 0.74 3.35x10-8 0.13 (0.06) 0.92 0.82-1.03
rs2290893 Shah et al. G 0.64 0.77 −201.4 3.7x10-8 −1.57x10-3 0.06 0.98 1.70x10-7 0.17 (0.05) 0.94 0.85-1.03

















Figure 3 Survival time varies with genetic variants influencing left ventricular hypertrophy.
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Key findings
To the best of our knowledge, our study represents the
first genetics study investigating LVH in T2DM. There
were 3 major findings in this study. Firstly, 63% of patients
with T2DM undergoing echocardiographic examination
had LVH, comparable to previous studies quoting 65% [9].
Secondly, the presence of LVH is independently associated
with greater mortality in our cohort compared to controls,
which is consistent with findings in previous studies [40].
Thirdly, in this genetics study of a large population of pa-
tients with T2DM in Scotland, SNPs previously identified
to be predictors of LVH in the general population were
replicated.The genetic basis of LVH in T2DM
Diabetes remains an independent predictor of LVH. How-
ever, not all patients with T2DM develop LVH and those
developing LVH do so to varying degrees [11], implying
LVH in T2DM has a genetic component. The genetic basis
of LVH has been studied in the general population and
variants in genes coding for ACE and the beta 1 adrener-
gic receptor were associated with LVH [41,42]. Variants at
these loci were not described in the previous GWAS pub-
lications looking at LVH and showed no sign of associ-
ation in our study. This has been a common feature of the
transition from candidate gene studies to GWAS, al-
though notable exceptions include the PPARG Pro12Ala
variant for T2DM [43].Table 3 Association between gene scoring based on
previously published SNPs and LVH
Gene score OR 95% Confidence intervals P value
Vasan SNPs 1.01 0.94-1.07 0.87
Shah SNPs 1.10 1.03-1.17 4.52x10-3
Vasan-Shah SNPs 1.09 1.03-1.16 6.24x10-3Considerations in investigating the genetic aspect of LVH
in T2DM
Our results suggest susceptibility to LVH in T2DM has a
detectable genetic component, though investigating any
aspect of LVH is intrinsically difficult as there is still dis-
cord regarding the optimum way to measure left ventricu-
lar size. Electrocardiography is the least expensive method
of detecting LVH but the sensitivity is poor in T2DM;
echocardiography is more sensitive [9]. Multiple methods
of assessing LVH by echocardiography exist including dir-
ect 2D measurements, calculation of relative wall thick-
ness and increase in left ventricular mass. Left ventricular
mass calculation by echocardiography is the gold standard
measure [5,29,30] but complex calculations are involved
making direct 2D measurements more popular clinically.
Lack of consensus in defining LVH has also made it diffi-
cult to compare genetic findings across studies. How LVH
influences outcome is the most important consideration
and we have demonstrated our definition strongly predicts
mortality. This is compounded by wide variation in the
populations from which cases of LVH were extracted prior
to genotyping. Initial studies looked at LVH familial corre-
lations [44] whilst later work sought variations in candidate
genes in hypertensive patients [17,18] in which LVH was
associated with variation in the GNB3 gene encoding the
G-protein β3 subunit.
Genetic variations frequently influence more than one
disease phenotype. A recent study by Povel et al. showed
SNPs associated with waist circumference (rs17782312
within MC4R) and insulin resistance (rs2943634 within
IRS1) were also associated with the metabolic syndrome
[45]. Genetic variants associated with features such as
serum lipid levels, insulin-resistance and waist circumfer-
ence in T2DM may also be associated with LVH. Add-
itionally, SNPs may interact with one clinical parameter to
influence another. Yin and colleagues found variation in 8
SNPs interacted with obesity to influence serum lipid
levels but did not influence serum lipid levels in normal
weight individuals [46]. SNPs may interact with other
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mote LVH in T2DM. This may be an area for future
research.
The role of GWAS
GWAS have broader scope to identify many genetic vari-
ants associated with a disease compared to candidate gene
studies. However, only two large, population-based GWAS
looking at LVH have been performed [20,21]. Vasan et al.
compared cases of echocardiographically defined LVH
with controls across 5 discovery cohorts (n=12 612) and 2
replication cohorts (n=4 094). Multiple SNPs were linked
to LVH, but none were replicated [20]. Shah et al. geno-
typed 10 256 individuals from 3 population based cohorts,
identifying cases of LVH by ECG criteria and comparing
to non-LVH controls. Four SNPs associated with LVH at
genome wide significance were also significant in their
replication cohort (n=11 777, [21]) but were not signifi-
cantly associated with LVH in the population based
ECHOgen study.
Physiological relevance of replicated SNPs
Two out of nine previously identified SNPs were repli-
cated at the 1 in 20 level, suggesting true replication.
Rs17132261 [20], is found near the SLC25A46 gene that
codes for a mitochondrial phosphate transporter [47]. Its
minor allele frequency (MAF) in the general population is
0.11 [48]. This proved to be a rare variant within our
population (MAF 0.01) and no homozygotes were identi-
fied. This was the only SNP that showed any sign of repli-
cation for left ventricular thickness in Stage 2 of the study
by Vasan et al., and is the only one that we have found to
be associated with LVH. Abnormal myocardial energetics
may be significant in cardiac pathophysiology [49], so vari-
ation here may logically be associated with LVH.
The second replicated SNP, rs2292462, was published
by Shah et al. [21] and is found in the NMB gene, which
has been linked with satiety and weight regulation [50].
Rs2292462 has a MAF of 0.34 in the general population
[48], with a MAF of 0.45 in our population. The Kaplan-
Meier plot in Figure 3B shows the guanine base variant
at rs229462 effects outcome in an allelic additive man-
ner. A SNP in IGF1R (rs4966014) became genome wide
significant (3.35 X 10-8) in the combined meta-analysis
after inclusion of our data, despite this not being signifi-
cant in our dataset. This was the most robustly associ-
ated gene in the study by Shah et al. The role of IGF1
signalling in cardiac hypertrophy is well established
[51,52] and the SNP lies immediately adjacent to a regu-
latory region recently identified by the ENCODE as be-
ing marked as transcriptional active in muscle cells, by
Histone acetylation and DNAse 1 sensitivity [51]. This
illustrates that it is unclear which, if any of the other loci
were not replicated due to a lack of power, or a truedifference in the determinants of echocardiographically
defined LVH and ECG-LVH.
Variation in rs2292462 was not predictive of obesity in
this study and was associated with LVH when weight
was taken into account. This suggests its link with obes-
ity is not driving its association with LVH and adverse
outcome in our population.
Study limitations
Firstly, values used for covariates were taken at regular
clinical visits rather than at the time of echocardiog-
raphy. Values closest to the date the echocardiogram
was performed were used for cases of LVH and values
closest to genotyping date were used for controls. Argu-
ably, if there had been changes in these covariates be-
tween the 2 time points it would have biased our results
towards the null.
Secondly, the retrospective nature of our study meant
we did not have echocardiographic data for our controls.
Our identification of controls was based on the hypothesis
patients undergoing echocardiography for any reasons
were more likely to have genetically-promoted structural
cardiac pathology. Patients on loop diuretics were ex-
cluded from the control population as they were deemed
more likely to have fluid retention related to undiagnosed
LVH with diastolic dysfunction. This method allowed us
to identify controls without clinically relevant LVH for
comparison. The clear difference in mortality between
cases of LVH and controls supports our identification of
controls, as does the fact that we replicated SNPs previ-
ously associated with LVH.
Thirdly, our sample size was small relative to previous
studies. Although only 2 previously published SNPs were
replicated, 4 published SNPs retained genome wide sig-
nificance following meta-analysis with our data. This
may indicate we had insufficient power to replicate the
other 2 SNPs using our data alone.
Conclusion
In a GWAS of a large population of patients with T2DM,
two SNPs previously identified as predictors of LVH were
replicated. It is hoped genetic findings will improve risk
stratification in diabetic patients so intensive preventative
measures can be taken in those at highest risk. Through
identification of genetic loci predicting the development of
LVH, it may be possible to identify new molecular drug
targets although more research is needed.
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